CoChat

Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study

Open access

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

BACKGROUND: There is a clinical concern that prescribing methylphenidate, the most common pharmacological treatment for attention-deficit hyperactivity disorder (ADHD), might increase the risk of psychotic events, particularly in young people with a history of psychosis. We aimed to determine whether the risk of psychotic events increases immediately after initiation of methylphenidate treatment or, in the longer term, 1 year after treatment initiation in adolescents and young adults with and without a previously diagnosed psychotic disorder. METHODS: In this cohort study, we used population-based observational data from the Swedish Prescribed Drug Register, the National Patient Register, and the Total Population Register, three population-based registers containing data on all individuals in Sweden, to attain data on sex, birth, death, migration, medication use, and psychotic events for all eligible participants. We screened individuals on these registers to identify those receiving methylphenidate treatment, and who were aged 12-30 years at the start of treatment, for their inclusion in the study. We used a within-individual design to compare the incidence of psychotic events in these individuals during the 12-week periods immediately before and after methylphenidate initiation. Longer term risk was assessed by comparing the incidence of psychotic events 12 weeks before methylphenidate initiation and during a 12-week period one calendar year before the initiation of methylphenidate with the incidence of these events during the 12-week period one calendar year after methylphenidate initiation. We estimated the incidence rate ratios (IRR) and 95% CIs of psychotic events after the initation of methylphenidate treatment, relative to the events before treatment, which were defined as any hospital visit (inpatient admission or outpatient attendance, based on data from the National Patient Register) because of psychosis, using the International Classification of Diseases version 10 definition. Analyses were stratified by whether the individual had a history of psychosis. FINDINGS: We searched the Swedish Prescribed Drug Register to find eligible individuals who had received methylphenidate between Jan 1, 2007 and June 30, 2012. 61 814 individuals were screened, of whom 23 898 (38·7%) individuals were assessed and 37 916 (61·3%) were excluded from the study because they were outside of the age criteria at the start of treatment, they had immigrated, emigrated, or died during the study period, or because they were administered other ADHD medications. The median age at methylphenidate initiation was 17 years, and a history of psychosis was reported in 479 (2·0%) participants. The IRR of psychotic events in the 12-week period after initiation of methylphenidate treatment relative to that in the 12-week period before treatment start was 1·04 (95% CI 0·80-1·34) in adolescents and young adults without a history of psychosis and 0·95 (0·69-1·30) among those with a history of psychosis. INTERPRETATION: Contrary to clinical concerns, we found no evidence that initiation of methylphenidate treatment increases the risk of psychotic events in adolescents and young adults, including in those individuals with a history of psychosis. Our study should reassure clinicians considering initiating methylphenidate treatment for ADHD in adolescents and young adults, and it challenges the widely held view in clinical practice that methylphenidate should be avoided, or its use restricted, in individuals with a history of psychosis. FUNDING: Swedish Research Council, National Institute of Mental Health, UK National Institute of Health Research Nottingham Biomedical Research Centre.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2215-0366(19)30189-0

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study design Period 1: the same 12 calendar weeks as period 2, 1 year before treatment. Period 2: 12 weeks before treatment initiation. Period 3: 12 weeks after treatment initiation. Period 4: the same 12 calendar weeks as period 2, 1 year after treatment.
Figure 1 Study design Period 1: the same 12 calendar weeks as period 2, 1 year before treatment. Period 2: 12 weeks before treatment initiation. Period 3: 12 weeks after treatment initiation. Period 4: the same 12 calendar weeks as period 2, 1 year after treatment.CC BY · PubMed Central
Figure 2 Incidence of hospital visits because of psychosis per 10 000 person-weeks, during the 64 weeks before and after methylphenidate treatment initiation in individuals with a history of psychosis
Figure 2 Incidence of hospital visits because of psychosis per 10 000 person-weeks, during the 64 weeks before and after methylphenidate treatment initiation in individuals with a history of psychosisCC BY · PubMed Central
Figure 3 Incidence of hospital visits because of psychosis per 10 000 person-weeks, during the 64 weeks before and after methylphenidate treatment initiation in individuals without a history of psychosis
Figure 3 Incidence of hospital visits because of psychosis per 10 000 person-weeks, during the 64 weeks before and after methylphenidate treatment initiation in individuals without a history of psychosisCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 69

Metadata

Authors
Hollis, C., Chen, Q., Chang, Z., Quinn, P. D., Viktorin, A., Lichtenstein, P., D'Onofrio, B., Landén, M., & Larsson, H.
Affiliations
  • University of Nottingham (GB)
  • Karolinska Institutet (SE)
  • Indiana University Bloomington (US)
  • Örebro University (SE)
Corresponding author
Hollis, Chris
Venue
The Lancet Psychiatry
Publisher
Elsevier BV
Published
2019-08
Volume
6
Issue
8
Pages
651-658
ISSN
2215-0366 (ISSN-L)
OpenAlex
W2949919329
Cited by
65
References
23
Citations by year
2026: 7 · 2025: 8 · 2024: 11 · 2023: 11 · 2022: 6 · 2021: 12 · 2020: 8 · 2019: 2
FWCI
5.58
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository@Nottingham (University of Nottingham) (publishedVersion, cc-by)
  • IUScholarWorks Open (Indiana University) (submittedVersion)
Funders
  • National Institute for Health and Care Research
  • Hjärnfonden (K20146–2X-146471–25–1)
  • Karolinska Institutet
  • National Institutes of Health (R00DA040727)
  • Vetenskapsrådet (20132–280)
  • NIHR Nottingham Biomedical Research Centre
  • National Institute on Drug Abuse
  • National Institute of Mental Health (1R01MH102221)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
methylphenidate, psychosis, attention deficit hyperactivity disorder, adolescents, young adults, incidence rate ratio, Sweden, ADHD medication
MeSH terms
Adolescent, Adult, Attention Deficit Disorder with Hyperactivity, Female, Humans, Male, Methylphenidate, Psychoses, Substance-Induced, Sweden, Cohort Studies, Incidence, Young Adult, Pharmacovigilance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study. https://app.cochat.ai/papers/10.1016/s2215-0366(19)30189-0
The paper
Hollis, C., Chen, Q., Chang, Z., Quinn, P. D., Viktorin, A., Lichtenstein, P., D'Onofrio, B., Landén, M., & Larsson, H. (2019). Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(19)30189-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.